Results 81 to 90 of about 8,158 (292)
Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
Optimizing treatments for type 2 diabetes mellitus (T2DM) remains an urgent issue. In addition to T2DM treatment strategies, such as glycaemic goals (glucose and glycated haemoglobin ?
Alina Babenko +4 more
doaj +1 more source
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone +3 more
wiley +1 more source
Incretins and SGLT2 inhibitors
Diabetes is one of the earliest diseases documented that mankind still hasn‘t found a cure against, with historical documents dating as far back as c. 1500 BCE. Modern medicine has certainly come a long way, as new treatments emerge regularly.
Agnarsson, Kristinn
core
The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets [PDF]
In healthy humans, the complex biochemical interplay between organs maintains metabolic homeostasis and pathological alterations in this process result in impaired metabolic homeostasis, causing metabolic diseases such as diabetes and obesity, which are ...
Steve Bain, Venkat Kanamarlapudi
core +1 more source
: Insulin infusion increases skeletal muscle microvascular blood flow (MBF) in healthy people but is impaired during insulin resistance. However, we have shown that eliciting insulin secretion via oral glucose loading in healthy people impairs muscle MBF,
Roberts-Thomson, KM +20 more
core +1 more source
Introduction: a significant improvement was shown in metabolic control at the early stages after BPD, which was associated with GLP-1 and was regardless of weight loss.Aim: to study the secretion of GLP-1, GIP, insulin and glucagon and their relationship
Ivan Ivanovich Dedov +3 more
doaj +1 more source
ABSTRACT Objective This study examined racial differences in weight loss and clinical response to glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) therapy among adults with obesity using real‐world data. Methods We retrospectively analyzed our institution's Research Data Warehouse (RDW) containing deidentified data from electronic health records ...
Jordan H. Mallette +4 more
wiley +1 more source
Severe periodontitis is known to aggravate diabetes mellitus, though molecular events related to that link have not been fully elucidated. Porphyromonas gingivalis, a major pathogen of periodontitis, expresses dipeptidyl peptidase 4 (DPP4), which is ...
Takayuki K. Nemoto +17 more
core +2 more sources
The Origin and Understanding of the Incretin Concept [PDF]
Gastrointestinal hormones that stimulate insulin secretion at physiological concentrations are incretins. This concept has recently attracted considerable attention in the wake of drugs developed from the gut hormone GLP-1 (glucagon-like peptide-1) for diabetes therapy.
openaire +4 more sources
Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps
ABSTRACT The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can
Robert L. Dubin +4 more
wiley +1 more source

